20/20 Biolabs, Inc.
AIDX
$0.60
$0.011.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.85M | 2.05M | 2.05M | 2.00M | 1.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.85M | 2.05M | 2.05M | 2.00M | 1.88M |
| Cost of Revenue | 1.35M | 1.45M | 1.41M | 1.48M | 1.44M |
| Gross Profit | 502.90K | 605.80K | 638.40K | 517.40K | 439.50K |
| SG&A Expenses | 3.89M | 3.34M | 3.38M | 4.19M | 4.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.82M | 5.35M | 5.68M | 6.71M | 7.05M |
| Operating Income | -3.97M | -3.29M | -3.63M | -4.72M | -5.17M |
| Income Before Tax | -5.11M | -3.70M | -3.64M | -4.69M | -5.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.11 | -3.70 | -3.64 | -4.69 | -5.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.11M | -3.70M | -3.64M | -4.69M | -5.10M |
| EBIT | -3.97M | -3.29M | -3.63M | -4.72M | -5.17M |
| EBITDA | -3.88M | -3.21M | -3.53M | -4.60M | -5.04M |
| EPS Basic | -0.79 | -0.85 | -0.85 | -1.07 | -1.16 |
| Normalized Basic EPS | -0.50 | -0.37 | -0.37 | -0.51 | -0.56 |
| EPS Diluted | -0.79 | -0.85 | -0.85 | -1.08 | -1.16 |
| Normalized Diluted EPS | -0.50 | -0.37 | -0.37 | -0.51 | -0.56 |
| Average Basic Shares Outstanding | 25.34M | 14.90M | 14.55M | 14.47M | 14.42M |
| Average Diluted Shares Outstanding | 25.34M | 19.72M | 19.37M | 19.29M | 19.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |